GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (NAS:TLIS) » Definitions » Market Cap

Talis Biomedical (Talis Biomedical) Market Cap : $16.36 Mil (As of May. 18, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Talis Biomedical's share price for the quarter that ended in Mar. 2024 was $8.75. Talis Biomedical's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 1.82 Mil. Therefore, Talis Biomedical's market cap for the quarter that ended in Mar. 2024 was $15.94 Mil.

Talis Biomedical's quarterly market cap increased from Sep. 2023 ($10.50 Mil) to Dec. 2023 ($13.57 Mil) and increased from Dec. 2023 ($13.57 Mil) to Mar. 2024 ($15.94 Mil).

Talis Biomedical's annual market cap declined from Dec. 2021 ($105.90 Mil) to Dec. 2022 ($11.94 Mil) but then increased from Dec. 2022 ($11.94 Mil) to Dec. 2023 ($13.57 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Talis Biomedical's Enterprise Value for Today is $-34.40 Mil.


Talis Biomedical Market Cap Historical Data

The historical data trend for Talis Biomedical's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talis Biomedical Market Cap Chart

Talis Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial - - 105.90 11.94 13.57

Talis Biomedical Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.17 13.10 10.50 13.57 15.94

Competitive Comparison of Talis Biomedical's Market Cap

For the Medical Devices subindustry, Talis Biomedical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talis Biomedical's Market Cap Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Market Cap distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's Market Cap falls into.



Talis Biomedical Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Talis Biomedical's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$7.45*1.82199
=$13.57

Talis Biomedical's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$8.75*1.82215
=$15.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Talis Biomedical  (NAS:TLIS) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Talis Biomedical Market Cap Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Talis Biomedical (Talis Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3400 Bridge Parkway, Redwood City, CA, USA, 94065
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
Executives
Andrew A Lukowiak officer: President, other: Chief Scientific Officer 1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich officer: Interim CFO CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser director, officer: President and CEO 561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan officer: Sr. Vice President, R&D 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063

Talis Biomedical (Talis Biomedical) Headlines

From GuruFocus

Talis Biomedical Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-20-2022

Talis Biomedical Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-30-2022

Talis Biomedical Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-29-2022

Talis Biomedical Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-19-2022